Sorafenib
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14456 publications
Corrigendum to "Dual-targeting liposomal delivery of sorafenib and docetaxel for enhanced synergistic therapy in advanced hepatocellular carcinoma" [Pharmaceut. Sci. Adv. 2 (2024) 100046].
Journal: Pharmaceutical science advances
Published: October 20, 2026
Thermosensitive RGD-modified liposomes co-loading Fe3O4 and sorafenib for synergistic photothermal-chemotherapy of hepatocellular carcinoma.
Journal: Dalton transactions (Cambridge, England : 2003)
Published: October 16, 2026
A systematic review of oral cancer drug therapies after metabolic bariatric surgery: what oncologists need to know about altered pharmacokinetics.
Journal: Expert opinion on drug metabolism & toxicology
Published: October 09, 2026
Rational design of a hierarchical HKUST-1@MXene nanocomposite modified electrode for high performance voltammetric sensing of sorafenib.
Journal: Analytical methods : advancing methods and applications
Published: October 07, 2026
Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma.
Journal: Immunotherapy
Published: October 05, 2026
Comment on "GLIM-Defined Malnutrition and Cachexia Are Associated with Overall Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib".
Journal: Clinical nutrition ESPEN
Published: October 01, 2026
Sorafenib-Induced Hand-Foot Skin Reaction in a Patient With Acute Myeloid Leukemia Following Haploidentical Stem Cell Transplantation: A Case Report.
Journal: Cureus
Published: September 24, 2026
Design, synthesis, and anticancer evaluation of Biginelli-derived DHPM-amide hybrids bearing clinically inspired kinase-directed pharmacophores: EGFR docking and DFT studies.
Journal: RSC advances
Published: September 15, 2026
Real-World Outcomes in the Evolving Second-Line Systemic Therapy Landscape in Hepatocellular Carcinoma: A Single-Institution Experience.
Journal: American journal of clinical oncology
Published: September 14, 2026
Integrating single-cell transcriptomics to construct an oncogene-driven prognostic model and elucidate metabolic-immune crosstalk in hepatocellular carcinoma.
Journal: Molecular & cellular oncology
Published: September 12, 2026
Last Updated: 11/08/2026